Federal Register / Vol. 80, No. 3 / Tuesday, January 6, 2015 / Notices 491 

Matters To Be Considered: The 

Committee will receive reports on the 

progress of the following subcommittees 

established to help NTIA develop new 

or revised strategies for responding 

more efficiently and effectively to 

fundamental technological, operational, 

and other trends to continue 

advancement of delivering spectrum 

products, services, and solutions that 

will support the ever-increasing demand 

for spectrum: 

1. Enforcement 

2. Transitional Sharing 

3. General Occupancy Measurements 

and Quantification of Federal 

Spectrum Use 

4. Spectrum Management via Databases 

5. Federal Access to Non-federal Bands 

(Bi-Directional Sharing) 

6. Spectrum Sharing Cost Recovery 

Alternatives 

7. Industry and Government 

Collaboration 

NTIA will post a detailed agenda on 

its Web site, http://www.ntia.doc.gov/

category/csmac, prior to the meeting. To 

the extent that the meeting time and 

agenda permit, any member of the 

public may speak to or otherwise 

address the Committee regarding the 

agenda items. See Open Meeting and 

Public Participation Policy, available at 

http://www.ntia.doc.gov/category/

csmac. 

Time and Date: The meeting will be 

held on February 18, 2015, from 1:00 

p.m. to 4:00 p.m., Eastern Standard 

Time. The times and the agenda topics 

are subject to change. The meeting will 

be available via two-way audio link and 

may be webcast. Please refer to NTIA’s 

Web site, http://www.ntia.doc.gov/

category/csmac, for the most up-to-date 

meeting agenda and access information. 

Place: The meeting will be held at the 

Raytheon Company, 1100 Wilson 

Boulevard, 20th Floor, Rosslyn, VA 

22209–2249. Public comments may be 

mailed to Commerce Spectrum 

Management Advisory Committee, 

National Telecommunications and 

Information Administration, 1401 

Constitution Avenue NW., Room 4099, 

Washington, DC 20230. The meeting 

will be open to the public and press on 

a first-come, first-served basis. Space is 

limited. All visitors, especially Foreign 

National Visitors, must send a written 

request to participate in the meeting on 

site. Visit request must be provided to 

Mr. Washington at BWashington@

ntia.doc.gov no later than February 6, 

2015. The public meeting is physically 

accessible to people with disabilities. 

Individuals requiring accommodations, 

such as sign language interpretation or 

other ancillary aids, are asked to notify 

Mr. Washington at (202) 482–6415 or 

BWashington@ntia.doc.gov at least ten 

(10) business days before the meeting. 

Status: Interested parties are invited 

to attend and to submit written 

comments to the Committee at any time 

before or after the meeting. Parties 

wishing to submit written comments for 

consideration by the Committee in 

advance of a meeting must send them to 

NTIA’s Washington, DC office at the 

above-listed address and comments 

must be received five (5) business days 

before the scheduled meeting date, to 

provide sufficient time for review. 

Comments received after this date will 

be distributed to the Committee, but 

may not be reviewed prior to the 

meeting. It would be helpful if paper 

submissions also include a compact disc 

(CD) in Word or PDF format. CDs should 

be labeled with the name and 

organizational affiliation of the filer. 

Alternatively, comments may be 

submitted electronically to 

BWashington@ntia.doc.gov. Comments 

provided via electronic mail also may be 

submitted in one or more of the formats 

specified above. 

Records: NTIA maintains records of 

all Committee proceedings. Committee 

records are available for public 

inspection at NTIA’s Washington, DC 

office at the address above. Documents 

including the Committee’s charter, 

member list, agendas, minutes, and any 

reports are available on NTIA’s 

Committee Web page at http://

www.ntia.doc.gov/category/csmac. 

Dated: December 30, 2014. 

Kathy D. Smith, 

Chief Counsel, National Telecommunications 

and Information Administration. 

[FR Doc. 2014–30872 Filed 1–5–15; 8:45 am] 

BILLING CODE 3510–60–P 

DEPARTMENT OF COMMERCE 

United States Patent and Trademark 

Office 

[Docket No.: PTO–P–2014–0068] 

Grant of Interim Extension of the Term 

of U.S. Patent No. 5,593,823; 

INTERCEPT® Blood System for Plasma 

AGENCY: United States Patent and 

Trademark Office, Commerce. 

ACTION: Notice of interim patent term 

extension. 

SUMMARY: The United States Patent and 

Trademark Office has issued an order 

granting a second interim extension 

under 35 U.S.C. 156(d)(5) for a one-year 

interim extension of the term of U.S. 

Patent No. 5,593,823. 

FOR FURTHER INFORMATION CONTACT: 

Mary C. Till by telephone at (571) 272– 

7755; by mail marked to her attention 

and addressed to the Commissioner for 

Patents, Mail Stop Hatch-Waxman PTE, 

P.O. Box 1450, Alexandria, VA 22313– 

1450; by fax marked to her attention at 

(571) 273–7755; or by email to 

Mary.Till@uspto.gov. 

SUPPLEMENTARY INFORMATION: Section 

156 of Title 35, United States Code, 

generally provides that the term of a 

patent may be extended for a period of 

up to five years if the patent claims a 

product, or a method of making or using 

a product, that has been subject to 

certain defined regulatory review, and 

that the patent may be extended for 

interim periods of up to one year if the 

regulatory review is anticipated to 

extend beyond the expiration date of the 

patent. 

On December 5, 2014, Cerus 

Corporation, the patent owner of record, 

timely filed an application under 35 

U.S.C. 156(d)(5) for a second interim 

extension of the term of U.S. Patent No. 

5,593,823. The patent claims the 

medical device INTERCEPT® Blood 

System for Plasma. The application 

indicates that a Premarket Approval 

Application (PMA) was submitted to the 

Food and Drug Administration (FDA) in 

four modules. The PMA Shell number 

BM120078 was assigned on December 5, 

2012. The first module was received by 

the FDA on March 1, 2013, the second 

module was received on June 3, 2013, 

by the FDA, the third module was 

received by the FDA on September 3, 

2013, and the fourth module was 

received by the FDA on November 29, 

2013. The medical device is currently 

undergoing regulatory review before the 

FDA for permission to market or use the 

product commercially. 

Review of the application indicates 

that, except for permission to market or 

use the product commercially, the 

subject patent would be eligible for an 

extension of the patent term under 35 

U.S.C. 156, and that the patent should 

be extended for one year as required by 

35 U.S.C. 156(d)(5)(B). Because it is 

apparent that the regulatory review 

period will continue beyond the 

extended expiration date of the patent, 

January 14, 2015, interim extension of 

the patent term under 35 U.S.C. 

156(d)(5) is appropriate. 

An interim extension under 35 U.S.C. 

156(d)(5) of the term of U.S. Patent No. 

5,593,823 is granted for a period of one 

year from the extended expiration date 

of the patent. 


tkelley on DSK3SPTVN1PROD with NOTICES
492 Federal Register / Vol. 80, No. 3 / Tuesday, January 6, 2015 / Notices 

Dated: December 23, 2014. 

Andrew Hirshfeld, 

Deputy Commissioner for Patent Examination 

Policy United States Patent and Trademark 

Office. 

[FR Doc. 2014–30945 Filed 1–5–15; 8:45 am] 

BILLING CODE 3510–16–P 

COMMODITY FUTURES TRADING 

COMMISSION 

Agency Information Collection 

Activities Under OMB Review 

AGENCY: Commodity Futures Trading 

Commission. 

ACTION: Notice. 

SUMMARY: In compliance with the 

Paperwork Reduction Act of 1995 

(PRA), this notice announces that the 

Information Collection Request (ICR) 

abstracted below has been forwarded to 

the Office of Management and Budget 

(OMB) for review and comment. The 

ICR describes the nature of the 

information collection and its expected 

costs and burden. 

DATES: Comments must be submitted on 

or before February 5, 2014. 

ADDRESSES: Comments may be 

submitted directly to the Office of 

Information and Regulatory Affairs 

(OIRA) in OMB, within 30 days of the 

notice’s publication, by email at 

OIRAsubmissions@omb.eop.gov. Please 

identify comments by ‘‘Financial 

Resource Reporting Requirements for 

Derivatives Clearing Organizations 

(OMB Control No. 3038–0066).’’ Please 

provide the Commission with a copy of 

all submitted comments at the address 

listed below. Comments may also be 

mailed to the Office of Information and 

Regulatory Affairs, Office of 

Management and Budget, Attention: 

Desk Officer for the Commodity Futures 

Trading Commission, 725 17th Street 

NW., Washington, DC 20503, and Eileen 

Chotiner, Division of Clearing and Risk, 

Commodity Futures Trading 

Commission, Three Lafayette Centre, 

1155 21st Street NW., Washington, DC 

20581. 

Comments may be also be submitted, 

regarding the burden estimated or any 

other aspect of the information 

collection, including suggestions for 

reducing the burden, identified by 

‘‘Financial Resource Requirements for 

Derivatives Clearing Organizations 

(OMB Control No. 3038–0066),’’ by any 

of the following methods: 

• Agency Web site, via its Comments 

Online process: http://

comments.cftc.gov. Follow the 

instructions for submitting comments 

through the Web site. 

• Mail: Send to Christopher 

Kirkpatrick, Secretary of the 

Commission, Commodity Futures 

Trading Commission, Three Lafayette 

Centre, 1155 21st Street NW., 

Washington, DC 20581. 

• Hand Delivery/Courier: Same as 

Mail, above. 

• Federal eRulemaking Portal: http:// 

www.regulations.gov. Follow the 

instructions for submitting comments. 

All comments must be submitted in 

English or, if not, accompanied by an 

English translation. Comments will be 

posted as received to http://

www.cftc.gov. You should submit only 

information that you wish to make 

available publicly. If you wish the 

Commission to consider information 

that is exempt from disclosure under the 

Freedom of Information Act, a petition 

for confidential treatment of the exempt 

information may be submitted according 

to the procedures set forth in § 145.9 of 

the Commission’s regulations. 

The Commission reserves the right, 

but shall have no obligation, to review, 

pre-screen, filter, redact, refuse or 

remove any or all of your submission 

from www.cftc.gov that it may deem to 

be inappropriate for publication, such as 

obscene language. All submissions that 

have been redacted or removed that 

contain comments on the merits of this 

matter will be retained in the public 

comment file and will be considered as 

required under applicable laws. 

FOR FURTHER INFORMATION CONTACT: 

Eileen Chotiner, Division of Clearing 

and Risk, Commodity Futures Trading 

Commission, Three Lafayette Centre, 

1155 21st Street NW., Washington, DC 

20581; (202) 418–5467; email: 

echotiner@cftc.gov, and refer to OMB 

Control number 3038–0066. This 

contact can also provide a copy of the 

ICR. 

SUPPLEMENTARY INFORMATION: This is a 

request for extension of a currently 

approved information collection. 

Title: ‘‘Financial Resource Reporting 

Requirements for Derivatives Clearing 

Organizations (OMB Control No. 3038– 

0066).’’ 

Abstract: Part 39 of the Commission’s 

regulations establishes financial 

reporting requirements for derivatives 

clearing organizations (DCOs), which 

are required to be registered with the 

Commission. The Commission will use 

the information in the reports to assess 

the DCOs’ compliance with the financial 

resource requirements for DCOs 

prescribed in the Commodity Exchange 

Act and Commission regulations. 

Burden Statement: The respondent 

burden for this collection is estimated to 

average 10 hours per response. 

Respondents/Affected Entities: 

Derivatives clearing organizations. 

Estimated Number of Respondents: 

14. 

Estimated Total Annual Burden on 

Respondents: 560 hours. 

Frequency of Collection: Quarterly 

and on occasion. 

Authority: 44 U.S.C. 3501 et seq. 

Dated: December 31, 2014. 

Christopher J. Kirkpatrick, 

Secretary of the Commission. 

[FR Doc. 2014–30950 Filed 1–5–15; 8:45 am] 

BILLING CODE 6351–01–P 

DEPARTMENT OF DEFENSE 

Office of the Secretary 

[Transmittal Nos. 13–45] 

36(b)(1) Arms Sales Notification 

AGENCY: Defense Security Cooperation 

Agency, Department of Defense. 

ACTION: Notice. 

SUMMARY: The Department of Defense is 

publishing the unclassified text of a 

section 36(b)(1) arms sales notification. 

This is published to fulfill the 

requirements of section 155 of Public 

Law 104–164 dated July 21, 1996. 

FOR FURTHER INFORMATION CONTACT: Ms. 

B. English, DSCA/DBO/CFM, (703) 601– 

3740. 

The following is a copy of a letter to 

the Speaker of the House of 

Representatives, Transmittals 13–45 

with attached transmittal, policy 

justification, and Sensitivity of 

Technology. 

Dated: December 31, 2014. 

Aaron Siegel, 

Alternate OSD Federal Register Liaison 

Officer, Department of Defense. 


tkelley on DSK3SPTVN1PROD with NOTICES